Yiyuan Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yiyuan Yin has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Roy A. Mariuzza
W.M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, USA
6 shared publications - Paul J. Carter
Department of Antibody Engineering, Genentech, Inc
4 shared publications - Christoph Spiess
Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
3 shared publications Diego Ellerman
B Department of Protein Chemistry , Genentech, Inc. , South San Francisco , CA , USA
3 shared publicationsGuanghui Han
D Department of Microchemistry, Proteomics and Lipidomics , Genentech, Inc. , South San Francisco , CA , USA
3 shared publicationsJianhui Zhou
A Department of Antibody Engineering , Genentech, Inc. , South San Francisco , CA , USA
3 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods, Figures S1-5 and Tables S1-8 from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Supplementary Materials and Methods, Figures S1-5 and Tables S1-8. Supplementary Materials and Methods: More detailed description of Materials and Methods for experiments. Figure S1: Structural analysis of the FGFR3-IIIb and R3Mab complex. Figure S2: Sequence analysis of the CDR H2 of selected FGFR2-positive clones. Figure S3: Superimposition of crystal structures of FGFR2-D2:2B.1.3 and FGFR3-D2D3:R3Mab. Figure S4: in vitro and in vivo studies of the 2B.1 antibody variants using the breast cancer cell line MFM-223x2.2. Figure S5: FGFR2 and FGFR3 expressions in gastric cancer cell line SNU-16. Table S1: Library design for recruiting FGFR2 binding specificity for R3Mab. Table S2: Library design for removing FGFR4 binding specificity from 2B.1.3. Table S3: Sequence identities between human FGFR. Table S4: Bidning affinities of selected 2B.1 variants for FGFR2 and FGFR3. Table S5: X-ray crystallography data collection and refinement statistics. Table S6: Binding affinities of R3Mab and 2B.1.3 for the D2 alone and D2D3 constructs of FGFR2 and FGFR3. Table S7: Residue differences between FGFR2 and FGFR4 at the positions making potential contacts with 2B.1.3. Table S8: 2B.1.3 variants that retain FGFR2 binding and show diminished binding to FGFR4.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods, Figures S1-5 and Tables S1-8 from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Supplementary Materials and Methods, Figures S1-5 and Tables S1-8. Supplementary Materials and Methods: More detailed description of Materials and Methods for experiments. Figure S1: Structural analysis of the FGFR3-IIIb and R3Mab complex. Figure S2: Sequence analysis of the CDR H2 of selected FGFR2-positive clones. Figure S3: Superimposition of crystal structures of FGFR2-D2:2B.1.3 and FGFR3-D2D3:R3Mab. Figure S4: in vitro and in vivo studies of the 2B.1 antibody variants using the breast cancer cell line MFM-223x2.2. Figure S5: FGFR2 and FGFR3 expressions in gastric cancer cell line SNU-16. Table S1: Library design for recruiting FGFR2 binding specificity for R3Mab. Table S2: Library design for removing FGFR4 binding specificity from 2B.1.3. Table S3: Sequence identities between human FGFR. Table S4: Bidning affinities of selected 2B.1 variants for FGFR2 and FGFR3. Table S5: X-ray crystallography data collection and refinement statistics. Table S6: Binding affinities of R3Mab and 2B.1.3 for the D2 alone and D2D3 constructs of FGFR2 and FGFR3. Table S7: Residue differences between FGFR2 and FGFR4 at the positions making potential contacts with 2B.1.3. Table S8: 2B.1.3 variants that retain FGFR2 binding and show diminished binding to FGFR4.
- Open Access
- 26 July 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (7) , 1254-1265
Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells
Multiple strategies have been developed to facilitate the efficient production of bispecific IgG (BsIgG) in single host cells. For example, we previously demonstrated near quantitative (≥90%) formation of BsIgG of different species and isotypes by combining ‘knob-into-hole’ mutations for heavy chain heterodimerization with engineered antigen-binding fragments (Fabs) for preferential cognate heavy/light chain pairing. Surprisingly, in this study we found high yield (>65%) of BsIgG1 without Fab engineering to be a common occurrence, i.e., observed for 33 of the 99 different antibody pairs evaluated. Installing charge mutations at both CH1/CL interfaces was sufficient for near quantitative yield (>90%) of BsIgG1 for most (9 of 11) antibody pairs tested with this inherent cognate chain pairing preference. Mechanistically, we demonstrate that a strong cognate pairing preference in one Fab arm can be sufficient for high BsIgG1 yield. These observed chain pairing preferences are apparently driven by variable domain sequences and can result from a few specific residues in the complementarity-determining region (CDR) L3 and H3. Transfer of these CDR residues into other antibodies increased BsIgG1 yield in most cases. Mutational analysis revealed that the disulfide bond between heavy and light chains did not affect the yield of BsIgG1. This study provides some mechanistic understanding of factors contributing to antibody heavy/light chain pairing preference and subsequently contributes to the efficient production of BsIgG in single host cells.
- 26 July 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (7) , 1254-1265
Open AccessElucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells
Multiple strategies have been developed to facilitate the efficient production of bispecific IgG (BsIgG) in single host cells. For example, we previously demonstrated near quantitative (≥90%) formation of BsIgG of different species and isotypes by combining ‘knob-into-hole’ mutations for heavy chain heterodimerization with engineered antigen-binding fragments (Fabs) for preferential cognate heavy/light chain pairing. Surprisingly, in this study we found high yield (>65%) of BsIgG1 without Fab engineering to be a common occurrence, i.e., observed for 33 of the 99 different antibody pairs evaluated. Installing charge mutations at both CH1/CL interfaces was sufficient for near quantitative yield (>90%) of BsIgG1 for most (9 of 11) antibody pairs tested with this inherent cognate chain pairing preference. Mechanistically, we demonstrate that a strong cognate pairing preference in one Fab arm can be sufficient for high BsIgG1 yield. These observed chain pairing preferences are apparently driven by variable domain sequences and can result from a few specific residues in the complementarity-determining region (CDR) L3 and H3. Transfer of these CDR residues into other antibodies increased BsIgG1 yield in most cases. Mutational analysis revealed that the disulfide bond between heavy and light chains did not affect the yield of BsIgG1. This study provides some mechanistic understanding of factors contributing to antibody heavy/light chain pairing preference and subsequently contributes to the efficient production of BsIgG in single host cells.
- Top Cited Papers
- 1 February 2018
- Published by Elsevier in Cell Metabolism
- Vol. 27 (2) , 461-469.e6
LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor
- 1 February 2018
- Published by Elsevier in Cell Metabolism
- Vol. 27 (2) , 461-469.e6
Top Cited PapersLEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor
- Open Access
- 8 December 2016
- Published by Taylor & Francis in mAbs
- Vol. 9 (2) , 213-230
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells
Bispecific IgG production in single host cells has been a much sought-after goal to support the clinical development of these complex molecules. Current routes to single cell production of bispecific IgG include engineering heavy chains for heterodimerization and redesign of Fab arms for selective pairing of cognate heavy and light chains. Here, we describe novel designs to facilitate selective Fab arm assembly in conjunction with previously described knobs-into-holes mutations for preferential heavy chain heterodimerization. The top Fab designs for selective pairing, namely variants v10 and v11, support near quantitative assembly of bispecific IgG in single cells for multiple different antibody pairs as judged by high-resolution mass spectrometry. Single-cell and in vitro-assembled bispecific IgG have comparable physical, in vitro biological and in vivo pharmacokinetics properties. Efficient single-cell production of bispecific IgG was demonstrated for human IgG1, IgG2 and IgG4 thereby allowing the heavy chain isotype to be tailored for specific therapeutic applications. Additionally, a reverse chimeric bispecific IgG2a with humanized variable domains and mouse constant domains was generated for preclinical proof-of-concept studies in mice. Efficient production of a bispecific IgG in stably transfected mammalian (CHO) cells was shown. Individual clones with stable titer and bispecific IgG composition for >120 days were readily identified. Such long-term cell line stability is needed for commercial manufacture of bispecific IgG. The single-cell bispecific IgG designs developed here may be broadly applicable to biotechnology research, including screening bispecific IgG panels, and to support clinical development.
- 8 December 2016
- Published by Taylor & Francis in mAbs
- Vol. 9 (2) , 213-230
Open AccessEfficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells
Bispecific IgG production in single host cells has been a much sought-after goal to support the clinical development of these complex molecules. Current routes to single cell production of bispecific IgG include engineering heavy chains for heterodimerization and redesign of Fab arms for selective pairing of cognate heavy and light chains. Here, we describe novel designs to facilitate selective Fab arm assembly in conjunction with previously described knobs-into-holes mutations for preferential heavy chain heterodimerization. The top Fab designs for selective pairing, namely variants v10 and v11, support near quantitative assembly of bispecific IgG in single cells for multiple different antibody pairs as judged by high-resolution mass spectrometry. Single-cell and in vitro-assembled bispecific IgG have comparable physical, in vitro biological and in vivo pharmacokinetics properties. Efficient single-cell production of bispecific IgG was demonstrated for human IgG1, IgG2 and IgG4 thereby allowing the heavy chain isotype to be tailored for specific therapeutic applications. Additionally, a reverse chimeric bispecific IgG2a with humanized variable domains and mouse constant domains was generated for preclinical proof-of-concept studies in mice. Efficient production of a bispecific IgG in stably transfected mammalian (CHO) cells was shown. Individual clones with stable titer and bispecific IgG composition for >120 days were readily identified. Such long-term cell line stability is needed for commercial manufacture of bispecific IgG. The single-cell bispecific IgG designs developed here may be broadly applicable to biotechnology research, including screening bispecific IgG panels, and to support clinical development.
- 21 November 2016
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 88 (24) , 12122-12127
Characterization of Chain Pairing Variants of Bispecific IgG Expressed in a Single Host Cell by High-Resolution Native and Denaturing Mass Spectrometry
Bispecific antibodies, including bispecific IgG, show some promise in clinical trials as a means to extend the therapeutic potential of antibodies. Bispecific IgG can be made by separate expression and purification of each parent half antibody followed by in vitro reconstitution. Generating bispecific IgG by coexpression of two different light and heavy chains in a single host cell is potentially more efficient because it obviates the need for two separate cell lines and purification processes. However, this workflow may produce unwanted mispaired IgG species in addition to the desired bispecific IgG. Development and identification of designs that facilitate cognate light chain pairing may benefit from more refined methods to identify and quantify low levels of mispaired IgG. Using an anti-IL-4/IL-13 bispecific IgG, a mass spectrometric characterization method was developed using native or denaturing conditions by direct infusion into an Exactive Plus Extended Mass Range Orbitrap instrument. The high mass resolving power of the instrument allows unambiguous identification and accurate quantification of all light and heavy chain pairing variants in a mixture of bispecific IgG assembled in vivo upon coexpression down to 1% impurity. Preferential pairing of the anti-IL-13 light chain to its cognate heavy chain was observed, which may be leveraged to guide the design of a single-cell solution for streamlined production of bispecific IgG. Additionally, the utility of native mass spectrometry in deconvoluting complex antibody mixtures and in antigen-binding experiments to understand the contribution of doubly light chain mispaired bispecific IgG was demonstrated.
- 21 November 2016
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 88 (24) , 12122-12127
Characterization of Chain Pairing Variants of Bispecific IgG Expressed in a Single Host Cell by High-Resolution Native and Denaturing Mass Spectrometry
Bispecific antibodies, including bispecific IgG, show some promise in clinical trials as a means to extend the therapeutic potential of antibodies. Bispecific IgG can be made by separate expression and purification of each parent half antibody followed by in vitro reconstitution. Generating bispecific IgG by coexpression of two different light and heavy chains in a single host cell is potentially more efficient because it obviates the need for two separate cell lines and purification processes. However, this workflow may produce unwanted mispaired IgG species in addition to the desired bispecific IgG. Development and identification of designs that facilitate cognate light chain pairing may benefit from more refined methods to identify and quantify low levels of mispaired IgG. Using an anti-IL-4/IL-13 bispecific IgG, a mass spectrometric characterization method was developed using native or denaturing conditions by direct infusion into an Exactive Plus Extended Mass Range Orbitrap instrument. The high mass resolving power of the instrument allows unambiguous identification and accurate quantification of all light and heavy chain pairing variants in a mixture of bispecific IgG assembled in vivo upon coexpression down to 1% impurity. Preferential pairing of the anti-IL-13 light chain to its cognate heavy chain was observed, which may be leveraged to guide the design of a single-cell solution for streamlined production of bispecific IgG. Additionally, the utility of native mass spectrometry in deconvoluting complex antibody mixtures and in antigen-binding experiments to understand the contribution of doubly light chain mispaired bispecific IgG was demonstrated.
- Open Access
- 9 September 2016
- Published by Taylor & Francis in mAbs
- Vol. 8 (8) , 1467-1476
Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry
Bispecific IgG are heterotetramers comprising 2 pairs of heavy and light chains. Co-expression of the 4 component chains in a single host cell typically yields the desired bispecific IgG plus up to 9 additional incorrect chain pairings. Several protein engineering strategies have been reported to facilitate the heterodimerization of antibody heavy chains or cognate pairing of antibody heavy and light chains. These technologies have been used to direct the efficient assembly of bispecific IgG in single host cells and minimize unwanted chain pairings. When purifying bispecific IgGs, the identification and quantification of low levels of closely related IgG contaminants are substantial analytical challenges. Here we have developed a robust high-throughput method for quantitative analysis of bispecific IgG preparations using novel online liquid chromatography in conjunction with an extended mass range Orbitrap-based high-resolution mass spectrometer. A mathematical method was developed to estimate the yields of the 2 isobaric species, namely the desired bispecific IgG and the light chain-scrambled IgG. The analytical methods described herein are anticipated to be broadly applicable to the development of bispecific IgG as drugs and potentially to other complex next-generation biotherapeutics.
- 9 September 2016
- Published by Taylor & Francis in mAbs
- Vol. 8 (8) , 1467-1476
Open AccessPrecise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry
Bispecific IgG are heterotetramers comprising 2 pairs of heavy and light chains. Co-expression of the 4 component chains in a single host cell typically yields the desired bispecific IgG plus up to 9 additional incorrect chain pairings. Several protein engineering strategies have been reported to facilitate the heterodimerization of antibody heavy chains or cognate pairing of antibody heavy and light chains. These technologies have been used to direct the efficient assembly of bispecific IgG in single host cells and minimize unwanted chain pairings. When purifying bispecific IgGs, the identification and quantification of low levels of closely related IgG contaminants are substantial analytical challenges. Here we have developed a robust high-throughput method for quantitative analysis of bispecific IgG preparations using novel online liquid chromatography in conjunction with an extended mass range Orbitrap-based high-resolution mass spectrometer. A mathematical method was developed to estimate the yields of the 2 isobaric species, namely the desired bispecific IgG and the light chain-scrambled IgG. The analytical methods described herein are anticipated to be broadly applicable to the development of bispecific IgG as drugs and potentially to other complex next-generation biotherapeutics.
- Open Access
- 1 October 2015
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 14 (10) , 2270-2278
Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
FGF receptors (FGFR) are attractive candidate targets for cancer therapy because they are dysregulated in several human malignancies. FGFR2 and FGFR3 can be inhibited potentially without disrupting adult tissue homeostasis. In contrast, blocking the closely related FGFR1 and FGFR4, which regulate specific metabolic functions, carries a greater safety risk. An anti-FGFR3 antibody was redesigned here to create function-blocking antibodies that bind with dual specificity to FGFR3 and FGFR2 but spare FGFR1 and FGFR4. R3Mab, a previously developed monospecific anti-FGFR3 antibody, was modified via structure-guided phage display and acquired additional binding to FGFR2. The initial variant was trispecific, binding tightly to FGFR3 and FGFR2 and moderately to FGFR4, while sparing FGFR1. The X-ray crystallographic structure indicated that the antibody variant was bound to a similar epitope on FGFR2 as R3Mab on FGFR3. The antibody was further engineered to decrease FGFR4-binding affinity while retaining affinity for FGFR3 and FGFR2. The resulting dual-specific antibodies blocked FGF binding to FGFR3 and FGFR2 and inhibited downstream signaling. Moreover, they displayed efficacy in mice against human tumor xenografts overexpressing FGFR3 or FGFR2. Thus, a monospecific antibody can be exquisitely tailored to confer or remove binding to closely related targets to expand and refine therapeutic potential. Mol Cancer Ther; 14(10); 2270–8. ©2015 AACR.
- 1 October 2015
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 14 (10) , 2270-2278
Open AccessRedesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
FGF receptors (FGFR) are attractive candidate targets for cancer therapy because they are dysregulated in several human malignancies. FGFR2 and FGFR3 can be inhibited potentially without disrupting adult tissue homeostasis. In contrast, blocking the closely related FGFR1 and FGFR4, which regulate specific metabolic functions, carries a greater safety risk. An anti-FGFR3 antibody was redesigned here to create function-blocking antibodies that bind with dual specificity to FGFR3 and FGFR2 but spare FGFR1 and FGFR4. R3Mab, a previously developed monospecific anti-FGFR3 antibody, was modified via structure-guided phage display and acquired additional binding to FGFR2. The initial variant was trispecific, binding tightly to FGFR3 and FGFR2 and moderately to FGFR4, while sparing FGFR1. The X-ray crystallographic structure indicated that the antibody variant was bound to a similar epitope on FGFR2 as R3Mab on FGFR3. The antibody was further engineered to decrease FGFR4-binding affinity while retaining affinity for FGFR3 and FGFR2. The resulting dual-specific antibodies blocked FGF binding to FGFR3 and FGFR2 and inhibited downstream signaling. Moreover, they displayed efficacy in mice against human tumor xenografts overexpressing FGFR3 or FGFR2. Thus, a monospecific antibody can be exquisitely tailored to confer or remove binding to closely related targets to expand and refine therapeutic potential. Mol Cancer Ther; 14(10); 2270–8. ©2015 AACR.
- Open Access
- 1 August 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (32) , 19796-19805
Identification of the Docking Site for CD3 on the T Cell Receptor β Chain by Solution NMR
- 1 August 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (32) , 19796-19805
Open AccessIdentification of the Docking Site for CD3 on the T Cell Receptor β Chain by Solution NMR
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4, 206
Structural and Biophysical Insights into the Role of CD4 and CD8 in T Cell Activation
T cell receptors (TCRs) recognize peptides presented by MHC molecules (pMHC) on an antigen-presenting cell (APC) to discriminate foreign from self-antigens and initiate adaptive immune responses. In addition, T cell activation generally requires binding of this same pMHC to a CD4 or CD8 co-receptor, resulting in assembly of a TCR–pMHC–CD4 or TCR–pMHC–CD8 complex and recruitment of Lck via its association with the co-receptor. Here we review structural and biophysical studies of CD4 and CD8 interactions with MHC molecules and TCR–pMHC complexes. Crystal structures have been determined of CD8αα and CD8αβ in complex with MHC class I, of CD4 bound to MHC class II, and of a complete TCR–pMHC–CD4 ternary complex. Additionally, the binding of these co-receptors to pMHC and TCR–pMHC ligands has been investigated both in solution and in situ at the T cell–APC interface. Together, these studies have provided key insights into the role of CD4 and CD8 in T cell activation, and into how these co-receptors focus TCR on MHC to guide TCR docking on pMHC during thymic T cell selection.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4, 206
Open AccessStructural and Biophysical Insights into the Role of CD4 and CD8 in T Cell Activation
T cell receptors (TCRs) recognize peptides presented by MHC molecules (pMHC) on an antigen-presenting cell (APC) to discriminate foreign from self-antigens and initiate adaptive immune responses. In addition, T cell activation generally requires binding of this same pMHC to a CD4 or CD8 co-receptor, resulting in assembly of a TCR–pMHC–CD4 or TCR–pMHC–CD8 complex and recruitment of Lck via its association with the co-receptor. Here we review structural and biophysical studies of CD4 and CD8 interactions with MHC molecules and TCR–pMHC complexes. Crystal structures have been determined of CD8αα and CD8αβ in complex with MHC class I, of CD4 bound to MHC class II, and of a complete TCR–pMHC–CD4 ternary complex. Additionally, the binding of these co-receptors to pMHC and TCR–pMHC ligands has been investigated both in solution and in situ at the T cell–APC interface. Together, these studies have provided key insights into the role of CD4 and CD8 in T cell activation, and into how these co-receptors focus TCR on MHC to guide TCR docking on pMHC during thymic T cell selection.
- 10 October 2012
- Published by Wiley in Immunological Reviews
- Vol. 250 (1) , 32-48
Structural basis for self‐recognition by autoimmune T‐cell receptors
Summary: T‐cell receptors (TCRs) recognize peptides presented by major histocompatibility complex molecules (pMHC) to discriminate between foreign and self‐antigens. Whereas T‐cell recognition of foreign peptides is essential for protection against microbial pathogens, recognition of self‐peptides by T cells that have escaped negative selection in the thymus can lead to autoimmune disease. Structural studies of autoimmune TCR–pMHC complexes have provided insights into the mechanisms underlying self‐recognition and escape from thymic deletion. Two broad categories of self‐reactive TCRs can be clearly distinguished: (i) TCRs with altered binding topologies to self‐pMHC and (ii) TCRs that bind self‐pMHC in the canonical diagonal orientation, but where there are structural defects or suboptimal anchors in the self‐ligand. For both categories, however, the overall stability of the autoimmune TCR–pMHC complex is markedly reduced compared to anti‐microbial complexes, allowing the autoreactive T cells to evade negative selection, yet retain the ability to be activated by self‐antigens in target organs. Additionally, the structures provide insights into TCR cross‐reactivity, which can contribute to autoimmunity by increasing the likelihood of self‐pMHC recognition. Efforts are now underway to understand the impact of structural alterations in autoimmune TCR–pMHC complexes on higher order assemblies involved in TCR signaling, as well as on immunological synapse formation.
- 10 October 2012
- Published by Wiley in Immunological Reviews
- Vol. 250 (1) , 32-48
Structural basis for self‐recognition by autoimmune T‐cell receptors
Summary: T‐cell receptors (TCRs) recognize peptides presented by major histocompatibility complex molecules (pMHC) to discriminate between foreign and self‐antigens. Whereas T‐cell recognition of foreign peptides is essential for protection against microbial pathogens, recognition of self‐peptides by T cells that have escaped negative selection in the thymus can lead to autoimmune disease. Structural studies of autoimmune TCR–pMHC complexes have provided insights into the mechanisms underlying self‐recognition and escape from thymic deletion. Two broad categories of self‐reactive TCRs can be clearly distinguished: (i) TCRs with altered binding topologies to self‐pMHC and (ii) TCRs that bind self‐pMHC in the canonical diagonal orientation, but where there are structural defects or suboptimal anchors in the self‐ligand. For both categories, however, the overall stability of the autoimmune TCR–pMHC complex is markedly reduced compared to anti‐microbial complexes, allowing the autoreactive T cells to evade negative selection, yet retain the ability to be activated by self‐antigens in target organs. Additionally, the structures provide insights into TCR cross‐reactivity, which can contribute to autoimmunity by increasing the likelihood of self‐pMHC recognition. Efforts are now underway to understand the impact of structural alterations in autoimmune TCR–pMHC complexes on higher order assemblies involved in TCR signaling, as well as on immunological synapse formation.